Press Releases April 1, 2026 08:00 PM

Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026

Merit Medical Systems announces Q1 2026 earnings release and investor call scheduled for April 30, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
MMSI

Merit Medical Systems, a global healthcare technology company specializing in proprietary medical devices, will release its financial results for Q1 2026 after market close on April 30, 2026, followed by an investor conference call.

Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026
MMSI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Merit Medical Systems focuses on medical devices used in interventional, diagnostic, and therapeutic procedures across multiple specialties including cardiology, radiology, oncology, critical care, and endoscopy.
  • The company plans to release financial results and hold a conference call on April 30, 2026.
  • Merit employs approximately 7,600 individuals and serves customers globally through a robust sales and clinical support team.

SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).

To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.

A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.

Contacts:
   PR/Media Inquiries:
Sarah Comstock
Merit MedicalInvestor Inquiries:
Mike Piccinino, CFA, IRC
ICR Healthcare+1-801-432-2864+1-443-213-0509sarah.comstock@[email protected]

Risks

  • Financial results may fall short of investor expectations impacting stock performance.
  • Market conditions in healthcare technology and medical device sectors could impact operational results.
  • Uncertainties related to global healthcare regulations and supply chain disruptions might affect company performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026